Skip to main content

Advertisement

SpringerLink
Log in

The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients

  • Original Article
  • Published:
The Pharmacogenomics Journal Submit manuscript

Abstract

We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study. Patients visited every 2 weeks after the first examination until the week 12 end point and were evaluated by the 17-item Hamilton Rating Scale for Depression (HAM-D-17) at each visit. FLV dose was changed in response to their clinical symptoms. The Gly272Asp polymorphism of the 5-HT1A receptor gene was identified by a PCR method. The subjects with the Asp allele had a significantly higher % reduction in the HAM-D-17 score than those with the Gly/Gly genotype at week 2 (P=0.009), week 6 (P=0.036), and week 12 (P=0.031). There was a significant difference in the genotype distribution between the responders and nonresponders. These results suggest that the Gly272Asp polymorphism of the 5-HT1A receptor gene may predict the response to FLV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Judd LL . Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 5–10.

    Article  PubMed  Google Scholar 

  2. National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993; 150: 1447–1465.

  3. Guscott R, Grof P . The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695–704.

    Article  CAS  PubMed  Google Scholar 

  4. Blier P, de Montigny C . Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220–226.

    Article  CAS  PubMed  Google Scholar 

  5. Blier P, de Montigny C, Chaput Y . Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7 (Suppl): 24S–35S.

    CAS  PubMed  Google Scholar 

  6. Hyttel J . Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 (Suppl 1): 19–26.

    Article  PubMed  Google Scholar 

  7. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157–203.

    CAS  PubMed  Google Scholar 

  8. Artigas F, Romero L, de Montigny C, Blier P . Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378–383.

    Article  CAS  PubMed  Google Scholar 

  9. Chaput Y, de Montigny C, Blier P . Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 333: 342–348.

    Article  CAS  Google Scholar 

  10. Bel N, Artigas F . Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15: 243–245.

    Article  CAS  PubMed  Google Scholar 

  11. Fuller RW . Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55: 163–167.

    Article  CAS  PubMed  Google Scholar 

  12. Rutter JJ, Gundlah C, Auerbach SB . Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994; 171: 183–186.

    Article  CAS  PubMed  Google Scholar 

  13. Bordet R, Thomas P, Dupuis B . Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998; 155: 1346–1351.

    Article  CAS  PubMed  Google Scholar 

  14. Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F . Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001; 21: 36–45.

    Article  CAS  PubMed  Google Scholar 

  15. Nakhai B, Nielsen DA, Linnoila M, Goldman D . Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem Biophys Res Commun 1995; 210: 530–536.

    Article  CAS  PubMed  Google Scholar 

  16. Erdmann J, Shimron-Abarbanell D, Cichon S, Albus M, Maier W, Lichtermann D et al. Systematic screening for mutations in the promoter and the coding region of the 5-HT1A gene. Am J Med Genet 1995; 60: 393–399.

    Article  CAS  PubMed  Google Scholar 

  17. Kawanishi Y, Harada S, Tachikawa H, Okubo T, Shiraishi H . Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia. Am J Med Genet 1998; 81: 434–439.

    Article  CAS  PubMed  Google Scholar 

  18. Nishiguchi N, Shirakawa O, Ono H, Nishimura A, Nushida H, Ueno Y et al. Lack of an association between 5-HT1A receptor gene structural polymorphisms and suicide victims. Am J Med Genet 2002; 114: 423–425.

    Article  PubMed  Google Scholar 

  19. Tome MB, Isaac MT, Harte R, Holland C . Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81–89.

    Article  CAS  PubMed  Google Scholar 

  20. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F . Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594–1597.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Research (JSPS) (#13670991 and #13671000).

Author information

Authors and Affiliations

  1. Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

    Y Suzuki, K Sawamura & T Someya

Authors
  1. Y Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Sawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Someya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Someya.

Additional information

DUALITY OF INTEREST

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzuki, Y., Sawamura, K. & Someya, T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 4, 283–286 (2004). https://doi.org/10.1038/sj.tpj.6500256

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500256

  • Springer Nature Limited

Keywords

This article is cited by

Search

Navigation